Abacavir Pharmacokinetics in Hepatic Dysfunction
نویسندگان
چکیده
منابع مشابه
Population pharmacokinetics of abacavir in pregnant women.
For the first time, a population approach was used to describe abacavir (ABC) pharmacokinetics in HIV-infected pregnant and nonpregnant women. A total of 266 samples from 150 women were obtained. No covariate effect (from age, body weight, pregnancy, or gestational age) on ABC pharmacokinetics was found. Thus, it seems unnecessary to adapt the ABC dosing regimen during pregnancy.
متن کاملAntiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in accelerated liver damage, compared with persons with chronic viral hepatitis alone. The use of highly active antiretroviral therapy (HAART) has led to a significant decrease in the morbidity and mortality associated with HIV-1 infection. A number of the medic...
متن کاملPopulation pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
The distribution of abacavir into the cerebrospinal fluid (CSF) was assessed by use of a population pharmacokinetic analysis. Plasma and CSF abacavir concentrations in 54 subjects were determined. The abacavir CSF/plasma ratio averaged 36% and increased throughout the dose interval. Abacavir penetrates into the CSF in adequate concentrations to inhibit local human immunodeficiency virus replica...
متن کاملEffect of Hepatic Dysfunction on Oral Cyclosporine Pharmacokinetics in Marrow Transplant Patients
The effect of hepatic dysfunction. defined as abnormal serum bilirubin level. on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied. divided among patients with no (< 1 .2 mg/dL). mild (1.2 to ...
متن کاملPhase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
We performed a phase I study of menogaril to determine if dosage reduction was required in patients with hepatic dysfunction and if the relationship between pharmacokinetics and leukopenia, previously defined in patients with normal hepatic and renal function, was altered. Eighteen patients received 27 courses of menogaril, of which 26 were evaluable for toxicity. Patient characteristics were m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2005
ISSN: 1058-4838,1537-6591
DOI: 10.1086/429247